Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
42
IDXG Quote, Financials, Valuation and Earnings
Last price:
$1.85
Seasonality move
:
-5.87%
Day range:
$1.82 - $1.85
52-week range:
$0.44 - $1.91
Dividend yield:
0%
P/E ratio:
6.88x
P/S ratio:
0.71x
P/B ratio:
--
Volume:
5.7K
Avg. volume:
12.3K
1-year change:
49.19%
Market cap:
$51.2M
Revenue:
$46.9M
EPS (TTM):
$0.27
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IDXG
Interpace Biosciences, Inc.
|
-- | -- | -- | -- | -- |
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
FUNI
Hypha Labs, Inc.
|
-- | -- | -- | -- | -- |
|
TMO
Thermo Fisher Scientific, Inc.
|
$11.9B | $6.45 | 4.86% | 33.13% | $666.46 |
|
VCYT
Veracyte, Inc.
|
$135.8M | $0.41 | 14.08% | 263.61% | $47.67 |
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IDXG
Interpace Biosciences, Inc.
|
$1.85 | -- | $51.2M | 6.88x | $0.00 | 0% | 0.71x |
|
FONR
FONAR Corp.
|
$18.54 | -- | $116.7M | 16.76x | $0.00 | 0% | 1.13x |
|
FUNI
Hypha Labs, Inc.
|
$0.03 | -- | $5.3M | 4.88x | $0.00 | 0% | 1.16x |
|
TMO
Thermo Fisher Scientific, Inc.
|
$509.82 | $666.46 | $191.5B | 28.74x | $0.43 | 0.34% | 4.33x |
|
VCYT
Veracyte, Inc.
|
$35.15 | $47.67 | $2.8B | 92.60x | $0.00 | 0% | 5.64x |
|
XWEL
XWELL, Inc.
|
$0.47 | -- | $2.7M | -- | $0.00 | 0% | 0.09x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IDXG
Interpace Biosciences, Inc.
|
115.19% | 2.171 | 56.7% | 1.24x |
|
FONR
FONAR Corp.
|
18.59% | 1.180 | 49.09% | 9.64x |
|
FUNI
Hypha Labs, Inc.
|
-716.88% | 1.421 | 34.57% | 0.07x |
|
TMO
Thermo Fisher Scientific, Inc.
|
42.44% | 0.926 | 18.08% | 1.25x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.144 | 1.49% | 5.74x |
|
XWEL
XWELL, Inc.
|
278.04% | 2.463 | 65.46% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IDXG
Interpace Biosciences, Inc.
|
$5.4M | $1.1M | 283.22% | -- | 13.08% | $1.8M |
|
FONR
FONAR Corp.
|
$10.4M | $3.2M | 4.68% | 5.84% | 12.26% | -$636K |
|
FUNI
Hypha Labs, Inc.
|
-$13.6K | -$536K | -28992.29% | -- | -- | $69.1K |
|
TMO
Thermo Fisher Scientific, Inc.
|
$4.6B | $2.3B | 7.8% | 13.23% | 18.85% | $3B |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
Interpace Biosciences, Inc. vs. Competitors
-
Which has Higher Returns IDXG or FONR?
FONAR Corp. has a net margin of 11.55% compared to Interpace Biosciences, Inc.'s net margin of 10.25%. Interpace Biosciences, Inc.'s return on equity of -- beat FONAR Corp.'s return on equity of 5.84%.
Company Gross Margin Earnings Per Share Invested Capital IDXGInterpace Biosciences, Inc.62.12% $0.03 $2M FONRFONAR Corp.40.11% $0.34 $201.3M -
What do Analysts Say About IDXG or FONR?
Interpace Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 494.6%. On the other hand FONAR Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Interpace Biosciences, Inc. has higher upside potential than FONAR Corp., analysts believe Interpace Biosciences, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings IDXGInterpace Biosciences, Inc.0 0 0 FONRFONAR Corp.0 0 0 -
Is IDXG or FONR More Risky?
Interpace Biosciences, Inc. has a beta of 1.115, which suggesting that the stock is 11.457% more volatile than S&P 500. In comparison FONAR Corp. has a beta of 1.002, suggesting its more volatile than the S&P 500 by 0.18499999999999%.
-
Which is a Better Dividend Stock IDXG or FONR?
Interpace Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FONAR Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Interpace Biosciences, Inc. pays -- of its earnings as a dividend. FONAR Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDXG or FONR?
Interpace Biosciences, Inc. quarterly revenues are $8.8M, which are smaller than FONAR Corp. quarterly revenues of $26M. Interpace Biosciences, Inc.'s net income of $1M is lower than FONAR Corp.'s net income of $2.7M. Notably, Interpace Biosciences, Inc.'s price-to-earnings ratio is 6.88x while FONAR Corp.'s PE ratio is 16.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Interpace Biosciences, Inc. is 0.71x versus 1.13x for FONAR Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXGInterpace Biosciences, Inc.0.71x 6.88x $8.8M $1M FONRFONAR Corp.1.13x 16.76x $26M $2.7M
-
Which has Higher Returns IDXG or FUNI?
Hypha Labs, Inc. has a net margin of 11.55% compared to Interpace Biosciences, Inc.'s net margin of --. Interpace Biosciences, Inc.'s return on equity of -- beat Hypha Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDXGInterpace Biosciences, Inc.62.12% $0.03 $2M FUNIHypha Labs, Inc.-- -- -$212.1K -
What do Analysts Say About IDXG or FUNI?
Interpace Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 494.6%. On the other hand Hypha Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Interpace Biosciences, Inc. has higher upside potential than Hypha Labs, Inc., analysts believe Interpace Biosciences, Inc. is more attractive than Hypha Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXGInterpace Biosciences, Inc.0 0 0 FUNIHypha Labs, Inc.0 0 0 -
Is IDXG or FUNI More Risky?
Interpace Biosciences, Inc. has a beta of 1.115, which suggesting that the stock is 11.457% more volatile than S&P 500. In comparison Hypha Labs, Inc. has a beta of 1.232, suggesting its more volatile than the S&P 500 by 23.248%.
-
Which is a Better Dividend Stock IDXG or FUNI?
Interpace Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hypha Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Interpace Biosciences, Inc. pays -- of its earnings as a dividend. Hypha Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDXG or FUNI?
Interpace Biosciences, Inc. quarterly revenues are $8.8M, which are larger than Hypha Labs, Inc. quarterly revenues of --. Interpace Biosciences, Inc.'s net income of $1M is higher than Hypha Labs, Inc.'s net income of -$562K. Notably, Interpace Biosciences, Inc.'s price-to-earnings ratio is 6.88x while Hypha Labs, Inc.'s PE ratio is 4.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Interpace Biosciences, Inc. is 0.71x versus 1.16x for Hypha Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXGInterpace Biosciences, Inc.0.71x 6.88x $8.8M $1M FUNIHypha Labs, Inc.1.16x 4.88x -- -$562K
-
Which has Higher Returns IDXG or TMO?
Thermo Fisher Scientific, Inc. has a net margin of 11.55% compared to Interpace Biosciences, Inc.'s net margin of 16.21%. Interpace Biosciences, Inc.'s return on equity of -- beat Thermo Fisher Scientific, Inc.'s return on equity of 13.23%.
Company Gross Margin Earnings Per Share Invested Capital IDXGInterpace Biosciences, Inc.62.12% $0.03 $2M TMOThermo Fisher Scientific, Inc.37.95% $5.21 $92.9B -
What do Analysts Say About IDXG or TMO?
Interpace Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 494.6%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $666.46 which suggests that it could grow by 30.72%. Given that Interpace Biosciences, Inc. has higher upside potential than Thermo Fisher Scientific, Inc., analysts believe Interpace Biosciences, Inc. is more attractive than Thermo Fisher Scientific, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXGInterpace Biosciences, Inc.0 0 0 TMOThermo Fisher Scientific, Inc.17 5 0 -
Is IDXG or TMO More Risky?
Interpace Biosciences, Inc. has a beta of 1.115, which suggesting that the stock is 11.457% more volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.928, suggesting its less volatile than the S&P 500 by 7.166%.
-
Which is a Better Dividend Stock IDXG or TMO?
Interpace Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.34% to investors and pays a quarterly dividend of $0.43 per share. Interpace Biosciences, Inc. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.7% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IDXG or TMO?
Interpace Biosciences, Inc. quarterly revenues are $8.8M, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $12.2B. Interpace Biosciences, Inc.'s net income of $1M is lower than Thermo Fisher Scientific, Inc.'s net income of $2B. Notably, Interpace Biosciences, Inc.'s price-to-earnings ratio is 6.88x while Thermo Fisher Scientific, Inc.'s PE ratio is 28.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Interpace Biosciences, Inc. is 0.71x versus 4.33x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXGInterpace Biosciences, Inc.0.71x 6.88x $8.8M $1M TMOThermo Fisher Scientific, Inc.4.33x 28.74x $12.2B $2B
-
Which has Higher Returns IDXG or VCYT?
Veracyte, Inc. has a net margin of 11.55% compared to Interpace Biosciences, Inc.'s net margin of 14.51%. Interpace Biosciences, Inc.'s return on equity of -- beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital IDXGInterpace Biosciences, Inc.62.12% $0.03 $2M VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About IDXG or VCYT?
Interpace Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 494.6%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.67 which suggests that it could grow by 35.61%. Given that Interpace Biosciences, Inc. has higher upside potential than Veracyte, Inc., analysts believe Interpace Biosciences, Inc. is more attractive than Veracyte, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXGInterpace Biosciences, Inc.0 0 0 VCYTVeracyte, Inc.8 2 1 -
Is IDXG or VCYT More Risky?
Interpace Biosciences, Inc. has a beta of 1.115, which suggesting that the stock is 11.457% more volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.288%.
-
Which is a Better Dividend Stock IDXG or VCYT?
Interpace Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Interpace Biosciences, Inc. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDXG or VCYT?
Interpace Biosciences, Inc. quarterly revenues are $8.8M, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. Interpace Biosciences, Inc.'s net income of $1M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, Interpace Biosciences, Inc.'s price-to-earnings ratio is 6.88x while Veracyte, Inc.'s PE ratio is 92.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Interpace Biosciences, Inc. is 0.71x versus 5.64x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXGInterpace Biosciences, Inc.0.71x 6.88x $8.8M $1M VCYTVeracyte, Inc.5.64x 92.60x $131.9M $19.1M
-
Which has Higher Returns IDXG or XWEL?
XWELL, Inc. has a net margin of 11.55% compared to Interpace Biosciences, Inc.'s net margin of -2.87%. Interpace Biosciences, Inc.'s return on equity of -- beat XWELL, Inc.'s return on equity of -224.93%.
Company Gross Margin Earnings Per Share Invested Capital IDXGInterpace Biosciences, Inc.62.12% $0.03 $2M XWELXWELL, Inc.17.32% -$0.26 $13M -
What do Analysts Say About IDXG or XWEL?
Interpace Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 494.6%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 1392.54%. Given that XWELL, Inc. has higher upside potential than Interpace Biosciences, Inc., analysts believe XWELL, Inc. is more attractive than Interpace Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXGInterpace Biosciences, Inc.0 0 0 XWELXWELL, Inc.0 0 0 -
Is IDXG or XWEL More Risky?
Interpace Biosciences, Inc. has a beta of 1.115, which suggesting that the stock is 11.457% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.511, suggesting its more volatile than the S&P 500 by 51.09%.
-
Which is a Better Dividend Stock IDXG or XWEL?
Interpace Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Interpace Biosciences, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDXG or XWEL?
Interpace Biosciences, Inc. quarterly revenues are $8.8M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. Interpace Biosciences, Inc.'s net income of $1M is higher than XWELL, Inc.'s net income of -$211K. Notably, Interpace Biosciences, Inc.'s price-to-earnings ratio is 6.88x while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Interpace Biosciences, Inc. is 0.71x versus 0.09x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXGInterpace Biosciences, Inc.0.71x 6.88x $8.8M $1M XWELXWELL, Inc.0.09x -- $7.3M -$211K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Sell
17
ICLR alert for Feb 13
ICON plc [ICLR] is down 39.93% over the past day.
Buy
67
CGNX alert for Feb 13
Cognex Corp. [CGNX] is up 36.39% over the past day.
Buy
77
IPGP alert for Feb 13
IPG Photonics Corp. [IPGP] is up 35.78% over the past day.
